A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) is a PHASE3 clinical asset sponsored by Principia Biopharma, a Sanofi Company in Immune Thrombocytopenia. SEO and diligence focus: Rilzabrutinib, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.